OPEN LETTER TO THE BOARD OF DIRECTORS OF THE WORLD BANK IN SUPPORT OF DR. NGOZI OKONJO-IWEALA’S CANDIDACY FOR PRESIDENT
Dear Honourable Board of Directors,
As the Graduates of the NEPAD Business Foundation African Leadership Programme (NBF-ALP) we proactively contribute towards changes that support good governance. We collaborate in ways that aim at ensuring inclusiveness [...]
OPEN LETTER TO THE BOARD OF DIRECTORS OF THE WORLD BANK IN SUPPORT OF DR. NGOZI OKONJO-IWEALA’S CANDIDACY FOR PRESIDENT
Dear Honourable Board of Directors,
As the Graduates of the NEPAD Business Foundation African Leadership Programme (NBF-ALP) we proactively contribute towards changes that support good governance. We collaborate in ways that aim at ensuring inclusiveness and improving institutions to support growth in developing nations. As future leaders we are conscious that identifying and supporting competent and deserving candidates is an important element in our work.
We are concerned with the historical practice among European and American representatives to preserve the Presidency of the World Bank among candidates from these regions. This practice erodes global inclusiveness, ignores emerging regions such as Africa, and overlooks formidable and competent leaders. As a consequence, the tacit arrangement threatens and weakens the World Bank’s credibility in low and middle-income countries, the current and future drivers of global economic development. There are candidates that are as good if not better than those appointed by tradition, such as Dr. Okonjo-Iweala.
Unlike other candidates, Dr. Okonjo-Iweala has a long history with the Bank starting as a development economist and more recently serving as its Managing Director. She was instrumental in various reform initiatives on economic development in Sub-Saharan Africa, the Middle-East, and East Asia. Dr. Okonjo-Iweala has the respect of many leaders of low and middle-income countries, and the international community. She is embedded in relevant social networks that will facilitate the implementation of real-world policies. Moreover, if the Bank is serious about gender equity, as it professes in many of its activities, then appointing Dr. Okonjo-Iweala will be a reaffirmation of your commitment to these ideals. To this end, we resolutely support Dr. Okonjo-Iweala’s candidacy for President of the World Bank. It’s an opportunity to implement the World Bank’s international strategy through a new brand of African leadership.
In many ways the Bank’s main challenge in low and middle-income countries is to root-out corruption at the level of governments and the private sector. Your credibility to do so depends on your willingness to acknowledge and build relationships with these very countries and acknowledge the rich human capital and capability of these nations. If the Bank looks beyond its outdated arrangement among European and American representatives, and seeks beyond your own confines for competent, alternative candidates, you will find that you will be lead to Dr. Okonjo-Iweala.
Yours sincerely
| João Carapinha | Layla Gibbons | Desyree Lotter |
| Anisa Mills | Aaron Shamu | Egideo Leite |
| Boma Anga | Ama Ayivor | Lungelwa Tyali |
| Oyesola Oyebanji |
Graduates of the NBF-ALP
______________________________________________________________________________
About the NEPAD Business Foundation (NBF) African Leadership Programme (ALP)
The NBF ALP concentrates on enhancing capacity and leadership potential of African top managers from the public and private sectors s well as NGOs.
About the NEPAD Business Foundation
The NBF operates in South Africa with extensive business networks in the Southern African sub-region and the Continent as a whole, driven by the vision to contribute to a vibrant African economy through private sector development, thus positioning the continent as competitive global player. The mission of the NBF is to support the delivery of the NEPAD objectives through the active participation of Africa’s private sector.
Carapinha, J. (2000) Continuing Professional Development in Human Resource Management. Journal of Modern Pharmacy, 7 (10), 1-6. Carapinha, J. (2003) Rational Self-Medication within a South African Context. The Journal of Modern Pharmacy, February 2003. Carapinha, J. (2005) Ethical Decision Making in Managed Health Care. South African Pharmaceutical Journal, 72 (2). Carapinha, J. (2005) Evidence-Based Pharmacy Practice. [...]
- Carapinha, J. (2000) Continuing Professional Development in Human Resource Management. Journal of Modern Pharmacy, 7 (10), 1-6.
- Carapinha, J. (2003) Rational Self-Medication within a South African Context. The Journal of Modern Pharmacy, February 2003.
- Carapinha, J. (2005) Ethical Decision Making in Managed Health Care. South African Pharmaceutical Journal, 72 (2).
- Carapinha, J. (2005) Evidence-Based Pharmacy Practice. South African Pharmaceutical Journal, 72 (4).
- Carapinha, J. (2006) The Value of Medicine in Improving the Quality of Care. Journal of South African Family Practice, 2006;48(10):6-10.
- Carapinha J. Producing Affordable Medicines in South Africa. In: Cohen JC, Illingworth P, Schuklenk U, editors. The Power of Pills. Maryland: Pluto Books; 2006. 251-259.
- Carapinha, J. (2008) Setting the Stage for Risk-Sharing Agreements: International Experiences and Outcomes-based Reimbursement. Journal of South African Family Practice, 2008;50(4):62-65.
- Carapinha, J. (2008) Policy Guidelines for Risk-sharing agreements in South Africa. Journal of South African Family Practice, 2008;50(5):43-46.
- Carapinha, J. (2008) Private pharmacies in an integrated approach to HIV/AIDS services. Journal of Social Aspects of HIV/AIDS, 2008 December; 5(4): 206-209.
- Carapinha, J. (2008) An Integrated Approach to HIV/AIDS Services in South Africa: Private Pharmacies and Policy Recommendations. Africa Policy Journal, Spring/Summer 2008 Edition. Volume 4. Harvard Kennedy School of Government.
- Carapinha, J. Ross-Degnan, D. Desta, AT. Wagner, A. (2011) Health insurance systems in five Sub-Saharan African countries: medicine benefits and data for decision making. Health Policy, 2011; 99(3): 193-202.
- Carapinha, J. Ross-Degnan, D. Vialle-Valentin, C. Wagner, A. (2012) Gender and treatment for HIV/AIDS, tuberculosis, and malaria in LMIC: A systematic review. (In Press)
Loraine shared her work on competition law to improve market efficiency with the ultimate aim of reducing medicine prices.
While much of her presentation concerns government as regulator, little was said about government as
market participant. For example, in certain circumstances, governments may wish to become a market player
in the [...]
Loraine shared her work on competition law to improve market efficiency with the ultimate aim of reducing medicine prices.
While much of her presentation concerns government as regulator, little was said about government as
market participant. For example, in certain circumstances, governments may wish to become a market player
in the provision of pharmaceutical services whether the private sector is unable or unwilling to do this work.
Victoria Hale, Medicines360′s CEO, believes the pharmaceutical business model is broken. Hale presented at the Unite for Sight conference in New Haven and informed delegates that pharma companies profit excessively from medicine sales and enourmous marketing budgets shadow R&D expenditure. Furthermore, she believes that society should purchase medicinal products from companies that benefit humanity.
[...]
Victoria Hale, Medicines360′s CEO, believes the pharmaceutical business model is broken. Hale presented at the Unite for Sight conference in New Haven and informed delegates that pharma companies profit excessively from medicine sales and enourmous marketing budgets shadow R&D expenditure. Furthermore, she believes that society should purchase medicinal products from companies that benefit humanity.
Talking about business models, Hale presented how Medicines360 operates, but if you take a closer look, how radically different is her business model compared to those of many pharma firms? Medicines360 diversifies its income and is partly dependent on sales for its financial sustainability – ditto for other pharma firms. Her business focus is medicines for neglected conditions among people in developing countries. Traditional pharma firms have also made some significant strides in this direction through innovative prize funds.
So how different is Medicines360? Based on what was presented at the conference, not much. Is their model a radical departure from current models? Perhaps a comparison of their balance sheet with those of traditional pharma firms may help, but I suspect that very little would be different.
Be as it may, Medicines360 may be the first step in the direction of a conversation about business models that enable all patients when in need to access medicines.
Joao, from New Haven, CT
Multinational medicine producers are fighting government action in Turkey to reduce medicine prices. Government regulation will definitely impact the bottom line but in the bigger picture (and from a multinational perspective) how much of it is actually relevant? A loss in Turkey is subsidised by a gain in a different country and it may require [...]
Multinational medicine producers are fighting government action in Turkey to reduce medicine prices. Government regulation will definitely impact the bottom line but in the bigger picture (and from a multinational perspective) how much of it is actually relevant? A loss in Turkey is subsidised by a gain in a different country and it may require a rebalancing of the tax reporting protocols for countries in which the company operates. Government regulation may also result in job losses but why do that when your competitors may find a profitable way of operating and may absorb that labour. All it does is reduce your ability to compete and increases your costs of hiring and retraining when periods of expansion roll around. Turkey’s medicine market is set to expand as are other emerging markets so all producers will benefit in the long run, so there’s no need to fight cheap medicines. Best regards, Joao
Sign up for our mailing list:
Thanks for visiting!
- Access Asia Pacific Biotech Brazil China Counterfeit developing countries Drug Prices Emerging Markets Ethics Generics Health Insurance HIV/AIDS India Industrial Policy Innovation Intellectual Property Managed health care medicines Nanotechnology News pharmaceutical pharmaceutical policy Pharmacists Pharmacoeconomics Philippines Poverty public policy Quality R&D Regulatory Affairs Reimbursement Risk sharing Russia Singapore South Africa Supply Chain Taiwan Trade Vaccines
Archives
- October 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- November 2011
- September 2011
- April 2011
- February 2011
- January 2011
- December 2010
- November 2010
- September 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- October 2008
- July 2008
- October 2007
- November 2006
- October 2006
- November 2005

